Table 3.

Projected budget impact (savings) over 1 year due to the introduction of CT-P10, and the number of additional patients that could subsequently gain access to rituximab treatment (base case scenario)

	RA		NHLa		CLL		Other indicationsb and off-label use		Totalc
	Budget impact, million EUR	No. of patients	Budget impact, million EUR	No. of patients	Budget impact, million EUR	No. of patients	Budget impact, million EUR	No. of patients	Budget impact, million EUR	No. of patients
Austria	−0.89	73	−1.45	58	−0.66	42	−0.33	20	−3.33	193
Belgium	−0.36	63	−0.58	50	−0.26	36	−0.13	17	−1.34	165
Bulgaria	−0.14	19	−0.22	15	−0.10	11	−0.05	5	−0.51	50
Croatia	−0.13	20	−0.22	16	−0.10	11	−0.05	5	−0.50	52
Czech Republic	−0.11	18	−0.17	14	−0.08	10	−0.04	5	−0.40	47
Finland	−0.70	64	−1.07	50	−0.49	36	−0.25	18	−2.51	168
France	−3.29	496	−5.28	392	−2.41	282	−1.22	137	−12.19	1306
Germany	−5.49	479	−8.91	379	−4.06	272	−2.05	132	−20.51	1262
Hungary	−0.23	35	−0.37	28	−0.17	20	−0.09	10	−0.85	92
Ireland	−0.26	37	−0.42	29	−0.19	21	−0.10	10	−0.96	96
Italy	−4.31	354	−6.90	280	−3.15	201	−1.60	98	−15.96	932
Netherlands	−0.81	105	−1.30	83	−0.59	59	−0.30	29	−3.01	276
Poland	−1.09	140	−1.75	111	−0.80	79	−0.40	38	−4.04	368
Portugal	−0.17	26	−0.27	21	−0.12	15	−0.06	7	−0.62	69
Romania	−0.31	45	−0.50	36	−0.23	26	−0.11	12	−1.15	119
Slovakia	−0.18	27	−0.29	21	−0.13	15	−0.07	7	−0.68	70
Slovenia	−0.11	14	−0.18	11	−0.08	8	−0.04	4	−0.41	36
Spain	−1.99	265	−3.28	210	−1.50	150	−0.75	72	−7.52	697
Sweden	−0.59	105	−0.94	83	−0.43	60	−0.22	29	−2.17	277
UK	−1.83	319	−2.94	252	−1.34	181	−0.68	88	−6.79	840
Estimates for European Union countries where IMS data is not available
Cyprus	−0.04	5	−0.07	4	−0.03	3	−0.02	1	−0.16	13
Denmark	−0.60	61	−0.96	48	−0.44	35	−0.22	17	−2.21	161
Estonia	−0.04	5	−0.07	4	−0.03	3	−0.02	1	−0.16	13
Greece	−0.36	62	−0.58	49	−0.27	35	−0.13	17	−1.35	163
Latvia	−0.05	7	−0.07	6	−0.03	4	−0.02	2	−0.17	19
Lithuania	−0.10	11	−0.17	8	−0.08	6	−0.04	3	−0.39	28
Luxembourg	−0.02	3	−0.03	3	−0.02	2	−0.01	1	−0.08	9
Malta	−0.02	2	−0.04	2	−0.02	1	−0.01	1	−0.08	6
Totalc	−24.22	2857	−39.02	2263	−17.80	1624	−9.00	787	−90.04	7531

Number of additional patients that could access rituximab treatment if all projected budget savings from the introduction of CT-P10 were allocated to this. Base case scenario assumed CT-P10 uptake of 30% and that the cost of CT-P10 was 70% of the cost of reference rituximab

CLL chronic lymphocytic leukemia, NHL non-Hodgkin’s lymphoma, RA rheumatoid arthritis

^aNHL comprised diffuse large B cell lymphoma and stage III–IV follicular lymphoma

^bGranulomatosis with polyangiitis (formerly Wegener’s granulomatosis) and microscopic polyangiitis

^cTotal values may differ slightly from the sum of individual values, due to rounding